Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ramucirumab as Second-Line Systemic Therapy in Hepatocellular Carcinoma.

Literature DB >> 30488020

Ramucirumab as Second-Line Systemic Therapy in Hepatocellular Carcinoma.

Masatoshi Kudo¹.

Abstract

Entities: Chemical Disease

Year: 2018 PMID： 30488020 PMCID： PMC6249592 DOI： 10.1159/000492534

Source DB: PubMed Journal: Liver Cancer ISSN： 1664-5553 Impact factor: 11.740

× No keyword cloud information.

4 in total

1. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Authors: Andrew X Zhu; Joon Oh Park; Baek-Yeol Ryoo; Chia-Jui Yen; Ronnie Poon; Davide Pastorelli; Jean-Frederic Blanc; Hyun Cheol Chung; Ari D Baron; Tulio Eduardo Flesch Pfiffer; Takuji Okusaka; Katerina Kubackova; Jorg Trojan; Javier Sastre; Ian Chau; Shao-Chun Chang; Paolo B Abada; Ling Yang; Jonathan D Schwartz; Masatoshi Kudo
Journal: Lancet Oncol Date: 2015-06-18 Impact factor: 41.316

2. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.

Authors: Masatoshi Kudo; Etsuro Hatano; Shinichi Ohkawa; Hirofumi Fujii; Akihide Masumoto; Junji Furuse; Yoshiyuki Wada; Hiroshi Ishii; Shuntaro Obi; Shuichi Kaneko; Seiji Kawazoe; Osamu Yokosuka; Masafumi Ikeda; Katsuaki Ukai; Sojiro Morita; Akihito Tsuji; Toshihiro Kudo; Mitsuo Shimada; Yukio Osaki; Ryosuke Tateishi; Gen Sugiyama; Paolo Benjamin Abada; Ling Yang; Takuji Okusaka; Andrew Xiuxuan Zhu
Journal: J Gastroenterol Date: 2016-08-22 Impact factor: 7.527

3. Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis.

Authors: Joon Oh Park; Baek-Yeol Ryoo; Chia-Jui Yen; Masatoshi Kudo; Ling Yang; Paolo B Abada; Rebecca Cheng; Mauro Orlando; Andrew X Zhu; Takuji Okusaka
Journal: Oncotarget Date: 2016-11-15

4. Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study.

Authors: Ian Chau; Joon Oh Park; Baek-Yeol Ryoo; Chia-Jui Yen; Ronnie Poon; Davide Pastorelli; Jean-Frédéric Blanc; Masatoshi Kudo; Tulio Pfiffer; Etsuro Hatano; Hyun Cheol Chung; Katerina Kopeckova; Jean-Marc Phelip; Giovanni Brandi; Shinichi Ohkawa; Chung-Pin Li; Takuji Okusaka; Yanzhi Hsu; Paolo B Abada; Andrew X Zhu
Journal: Br J Cancer Date: 2018-05-29 Impact factor: 7.640

4 in total

5 in total

Review 1. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.

Authors: Masatoshi Kudo
Journal: Liver Cancer Date: 2020-11-17 Impact factor: 11.740

2. Novel lysophosphatidic acid receptor 6 antagonists inhibit hepatocellular carcinoma growth through affecting mitochondrial function.

Authors: Davide Gnocchi; Saketh Kapoor; Patrizia Nitti; Maria Maddalena Cavalluzzi; Giovanni Lentini; Nunzio Denora; Carlo Sabbà; Antonio Mazzocca
Journal: J Mol Med (Berl) Date: 2019-12-20 Impact factor: 4.599